These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

217 related articles for article (PubMed ID: 17655683)

  • 1. Current safety and tolerability issues in men with erectile dysfunction receiving PDE5 inhibitors.
    Hellstrom WJ
    Int J Clin Pract; 2007 Sep; 61(9):1547-54. PubMed ID: 17655683
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phosphodiesterase type 5 inhibitor therapy: identifying and exploring what attributes matter more to clinicians and patients in the management of erectile dysfunction.
    Axilrod AC
    Curr Med Res Opin; 2007 Dec; 23(12):3189-98. PubMed ID: 17991309
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Non-arteritic anterior ischemic optic neuropathy (NAION) and phosphodiesterase type-5 inhibitors.
    Bella AJ; Brant WO; Lue TF; Brock GB
    Can J Urol; 2006 Oct; 13(5):3233-8. PubMed ID: 17076943
    [TBL] [Abstract][Full Text] [Related]  

  • 4. PDE5 inhibitors: are there differences?
    Carson CC
    Can J Urol; 2006 Feb; 13 Suppl 1():34-9. PubMed ID: 16526979
    [TBL] [Abstract][Full Text] [Related]  

  • 5. PDE5 inhibitors beyond erectile dysfunction.
    Sandner P; Hütter J; Tinel H; Ziegelbauer K; Bischoff E
    Int J Impot Res; 2007; 19(6):533-43. PubMed ID: 17625575
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Novel indications for phosphodiesterase type 5 inhibitors].
    Rosenkranz S; Caglayan E; Erdmann E
    Med Klin (Munich); 2007 Aug; 102(8):617-30. PubMed ID: 17694282
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Combining testosterone and PDE5 inhibitors in erectile dysfunction: basic rationale and clinical evidences.
    Greco EA; Spera G; Aversa A
    Eur Urol; 2006 Nov; 50(5):940-7. PubMed ID: 16979814
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The safety profile of tadalafil as prescribed in general practice in England: results from a prescription-event monitoring study involving 16 129 patients.
    Hazell L; Cornelius V; Wilton LV; Shakir SA
    BJU Int; 2009 Feb; 103(4):506-14. PubMed ID: 18990133
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Tadalafil for erectile dysfunction: excellent safety and tolerance].
    Bai WJ
    Zhonghua Nan Ke Xue; 2009 Jan; 15(1):92-5. PubMed ID: 19288756
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phosphodiesterase type 5 inhibitors: the day after.
    Hatzimouratidis K; Hatzichristou D
    Eur Urol; 2007 Jan; 51(1):75-88; discussion 89. PubMed ID: 16949200
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Global experiences with vardenafil in men with erectile dysfunction and underlying conditions.
    Eardley I; Lee JC; Guay AT
    Int J Clin Pract; 2008 Oct; 62(10):1594-603. PubMed ID: 18822030
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Erectile dysfunction and hypertension.
    Kloner R
    Int J Impot Res; 2007; 19(3):296-302. PubMed ID: 17151696
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The therapeutic dilemma: how to use short-acting PDE5 inhibitor drugs.
    Fabbri A; Aversa A
    Int J Androl; 2005 Dec; 28 Suppl 2():69-73. PubMed ID: 16236069
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phosphodiesterase type 5 (PDE5) inhibitors for the treatment of erectile dysfunction.
    Dorsey P; Keel C; Klavens M; Hellstrom WJ
    Expert Opin Pharmacother; 2010 May; 11(7):1109-22. PubMed ID: 20402554
    [TBL] [Abstract][Full Text] [Related]  

  • 15. PDE5 inhibitors for LUTS.
    Mouli S; McVary KT
    Prostate Cancer Prostatic Dis; 2009; 12(4):316-24. PubMed ID: 19687801
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Safety and tolerability of Vardenafil].
    Hong K; Jiang H
    Zhonghua Nan Ke Xue; 2006 Sep; 12(9):857-60. PubMed ID: 17009542
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Erectile dysfunction drugs and risk of anterior ischaemic optic neuropathy: casual or causal association?
    Danesh-Meyer HV; Levin LA
    Br J Ophthalmol; 2007 Nov; 91(11):1551-5. PubMed ID: 17947271
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Patterns of switching phosphodiesterase type 5 inhibitors in the treatment of erectile dysfunction: results from the Erectile Dysfunction Observational Study.
    Hatzichristou D; Haro JM; Martin-Morales A; von Keitz A; Riley A; Bertsch J; Belger M; Wolka AM; Beardsworth A;
    Int J Clin Pract; 2007 Nov; 61(11):1850-62. PubMed ID: 17850306
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Erectile dysfunction, discrepancy between high prevalence and low utilization of treatment options: results from the 'Cottbus Survey' with 10 000 men.
    May M; Gralla O; Knoll N; Fenske S; Spivak I; Rönnebeck C; Hoffmann M; Lenk S; Hoschke B
    BJU Int; 2007 Nov; 100(5):1110-5. PubMed ID: 17922788
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The evolving role of testosterone in the treatment of erectile dysfunction.
    Shabsigh R; Rajfer J; Aversa A; Traish AM; Yassin A; Kalinchenko SY; Buvat J
    Int J Clin Pract; 2006 Sep; 60(9):1087-92. PubMed ID: 16939550
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.